Pletaal

Cilostazol

Ischemic symptoms including ulceration, pain & coldness of the extremities, in chronic arterial occlusion (Buerger's disease, arteriosclerosis obliterans, diabetic peripheral angiopathy). Prevention of recurrence of cerebral infarction (excluding cardiogenic cerebral embolism).

Adult 100 mg bd. Dosage may be adjusted according to age & severity of symptoms.

Should be taken on an empty stomach.

Hypersensitivity. Patients w/ CHF; hemorrhage (eg, hemophilia, increased capillary fragility, hemoptysis & intracranial, upper GI, urinary tract & vitreous body hemorrhage) & known predisposition to bleeding (eg, active peptic ulceration, recent haemorrhagic stroke or surgery, proliferative diabetic retinopathy, poorly controlled HTN). Pregnant or may possibly become pregnant. Lactation.

Discontinue or reduce dose if an excessive increase in pulse rate is observed in patients w/ coronary artery stenosis. Discontinue if there is clinical or lab evidence of hematological abnormalities. Stabilize patients w/ cerebral infarction prior to use. Patients during menstruation; w/ complication of coronary artery stenosis; DM or abnormal glucose tolerance; HTN w/ consistently high BP eg, malignant HTN; ventricular transposition, tachycardia & fibrillation, atrial transposition, fibrillation & flutter, multifocal ventricular ectopics & prolongation of the QTc interval; risk of sigmoid-shaped interventricular septum. Closely monitor patients for any anginal symptoms eg, chest pain; development of a new systolic murmur or cardiac symptoms after starting treatment. Perform full blood count if infection is suspected or if there is any other clinical evidence of blood dyscrasia. Concomitant use w/ anticoagulants, antiplatelet drugs, thrombolytic drugs, prostaglandin E or its derivatives. Increased lovastatin AUC. May cause dizziness thus caution in driving or operating machinery. Severe renal failure (CrCl 25 mL/min). Moderate or severe hepatic failure. Childn. Elderly.

CHF, MI, angina pectoris; hemorrhage; gastric or duodenal ulcers; thrombocytopenia; interstitial pneumonia; hepatic dysfunction; acute renal failure.

May cause bleeding tendency w/ anticoagulants (eg, warfarin), antiplatelet drugs (eg, aspirin & ticlopidine), thrombolytic drugs (eg, urokinase & alteplase), prostaglandin E or its derivatives (eg, alprostadil & limaprost alfadex). Blood conc may be increased & effect may be potentiated w/ CYP3A4 & CYP2C9 inhibitors eg, cimetidine, diltiazem, erythromycin, ketoconazole, lansoprazole, itraconazole, miconazole, omeprazole, HIV-1 PIs). Caution w/ grapefruit juice. Potential additive hypotensive effect w/ reflex tachycardia w/ any other agent w/ potential to reduce BP or vasodilators eg, dihydropyridine Ca channel blockers.

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

POM